Neurocrine Bio stock retains outperform rating on robust pipeline
Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently ...
pharmaphorum3 天
SOM's AI-discovered drug shows promise in Huntington's disease
SOM intends to advance the drug into a phase 2b trial later this year, and reckons it has key advantages over Lundbeck's Xenazine (tetrabenazine), a well-established VMAT2 inhibitor used to treat ...